The Effects of the COVID-19 Lockdown on Severe Asthma in Patients Taking Biologic Therapy and Air Pollution

H. Al-Jahdali, Mohammad A Khan, R. Rajkumar, M. Al-Gamedi, H. Al-Hayyan, A. Al-Harbi
{"title":"The Effects of the COVID-19 Lockdown on Severe Asthma in Patients Taking Biologic Therapy and Air Pollution","authors":"H. Al-Jahdali, Mohammad A Khan, R. Rajkumar, M. Al-Gamedi, H. Al-Hayyan, A. Al-Harbi","doi":"10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1290","DOIUrl":null,"url":null,"abstract":"Background: The curfews and lockdowns imposed during the COVID 19 pandemic may decreased volume of traffic and reduced air pollution. In addition, social distancing measures may contribute to reduce infection and asthma exacerbation. Objective: To assess asthma control and asthma medication use among sever asthmatics on biologics before and after COVID-19 pandemic Method: This is a cross-sectional survey study of patients with severe asthma receiving biologic therapy at King Abdulaziz Medical City-Riyadh (KAMC-R), Saudi Arabia. We looked at the effects of the COVID19 lockdown on this cohort of sever asthmatics on biologic therapy from March till June 2020 over a period of 12 weeks. We investigated changes in patients symptoms and asthma control using the asthma control test (ACT) score and other parameters including, emergency department (ED) visits, hospitalizations, use of oral prednisolone, changes in inhaler therapy, frequency of bronchodilators use and patient perception of their symptoms before and after the lockdown period. Results: A total of 56, Female 39;(69%0;mean age ± SD 47.4 ± 13.8 years. The duration of bronchial asthma since diagnosis range from 4-30 years. Most patients had been treated with Omalizumab (47;84%);the rest received Mepolizumab (7;12.5%) and Dupilumab (2;3.6%). All these patients had been on biologic therapy for 5 months, range from 5 to 120 months. Most of the patients (45;80.4%) agreed that their symptoms of asthma had improved with biologic therapy. Most of the patients felt overall asthma symptoms is better after curfew and lockdown 28 (50%). Less use of bronchodilators post curfew reported in 38% of the patients. Asthma control (≥20) using ACT score was significantly higher among patients in post curfew and lockdown period compared to pre curfew period 34(61.7%) and 23 (41%), (p.0.001) respectively. Conclusion: Asthma control was better post curfew and lockdown. Decrease in air pollution and social distances may be contribute factor.","PeriodicalId":320542,"journal":{"name":"TP3. TP003 COVID-19 INFECTIONS, MECHANISMS, AND CLINICAL IMPLICATIONS","volume":"53 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"TP3. TP003 COVID-19 INFECTIONS, MECHANISMS, AND CLINICAL IMPLICATIONS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1290","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background: The curfews and lockdowns imposed during the COVID 19 pandemic may decreased volume of traffic and reduced air pollution. In addition, social distancing measures may contribute to reduce infection and asthma exacerbation. Objective: To assess asthma control and asthma medication use among sever asthmatics on biologics before and after COVID-19 pandemic Method: This is a cross-sectional survey study of patients with severe asthma receiving biologic therapy at King Abdulaziz Medical City-Riyadh (KAMC-R), Saudi Arabia. We looked at the effects of the COVID19 lockdown on this cohort of sever asthmatics on biologic therapy from March till June 2020 over a period of 12 weeks. We investigated changes in patients symptoms and asthma control using the asthma control test (ACT) score and other parameters including, emergency department (ED) visits, hospitalizations, use of oral prednisolone, changes in inhaler therapy, frequency of bronchodilators use and patient perception of their symptoms before and after the lockdown period. Results: A total of 56, Female 39;(69%0;mean age ± SD 47.4 ± 13.8 years. The duration of bronchial asthma since diagnosis range from 4-30 years. Most patients had been treated with Omalizumab (47;84%);the rest received Mepolizumab (7;12.5%) and Dupilumab (2;3.6%). All these patients had been on biologic therapy for 5 months, range from 5 to 120 months. Most of the patients (45;80.4%) agreed that their symptoms of asthma had improved with biologic therapy. Most of the patients felt overall asthma symptoms is better after curfew and lockdown 28 (50%). Less use of bronchodilators post curfew reported in 38% of the patients. Asthma control (≥20) using ACT score was significantly higher among patients in post curfew and lockdown period compared to pre curfew period 34(61.7%) and 23 (41%), (p.0.001) respectively. Conclusion: Asthma control was better post curfew and lockdown. Decrease in air pollution and social distances may be contribute factor.
COVID-19封锁对生物治疗重症哮喘患者和空气污染的影响
背景:在2019冠状病毒病大流行期间实施的宵禁和封锁可能会减少交通量并减少空气污染。此外,保持社交距离措施可能有助于减少感染和哮喘恶化。目的:了解新冠肺炎大流行前后重症哮喘患者的哮喘控制情况和使用生物制剂治疗哮喘的情况。方法:对沙特阿拉伯利雅得阿卜杜勒阿齐兹国王医疗城(KAMC-R)接受生物治疗的重症哮喘患者进行横贯调查研究。我们在2020年3月至6月的12周时间里研究了covid - 19封锁对这组严重哮喘患者生物治疗的影响。我们通过哮喘控制试验(ACT)评分和其他参数调查了患者症状和哮喘控制的变化,这些参数包括急诊科(ED)就诊次数、住院次数、口服强的松龙的使用、吸入器治疗的变化、支气管扩张剂的使用频率以及患者在封锁期前后对症状的感知。结果:共56例,女性39例;(69%)0岁;平均年龄±SD 47.4±13.8岁。支气管哮喘自诊断以来持续时间为4-30年。大多数患者接受了Omalizumab(47;84%),其余患者接受了Mepolizumab(7;12.5%)和Dupilumab(2;3.6%)。所有患者均接受生物治疗5个月,治疗时间从5个月到120个月不等。大多数患者(45例,80.4%)认为生物治疗改善了哮喘症状。大多数患者认为宵禁和封锁后整体哮喘症状好转28(50%)。38%的患者在宵禁后较少使用支气管扩张剂。宵禁后和封锁期间使用ACT评分的哮喘控制(≥20)患者分别高于宵禁前34(61.7%)和23(41%),差异有统计学意义(p.0.001)。结论:宵禁和封城后哮喘控制效果较好。空气污染和社会距离的减少可能是促成因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信